|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012854,
umls-concept:C0031715,
umls-concept:C0079419,
umls-concept:C0086418,
umls-concept:C0332157,
umls-concept:C0332324,
umls-concept:C0332325,
umls-concept:C0449438,
umls-concept:C0450442,
umls-concept:C0542341,
umls-concept:C1514162,
umls-concept:C1516211
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2003-12-3
|
|
pubmed:abstractText |
Resistance to chemotherapeutic drugs is a hallmark of many human cancers, which can occur independent of p53 gene status; however, the presence of wild-type p53 in chemorefractory tumors confers greater resistance to cisplatin, but such tumors do not display complete cross-resistance to the platinum analog (1R,2R-diaminocyclohexane)(trans-diacetato)(dichloro)platinumIV (DACH-Ac-Pt). In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/(diaminocyclohexane)(diacetato)(dich...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclins,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0171-5216
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
129
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
709-18
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14513366-Antineoplastic Agents,
pubmed-meshheading:14513366-Blotting, Western,
pubmed-meshheading:14513366-Cell Line, Tumor,
pubmed-meshheading:14513366-Cisplatin,
pubmed-meshheading:14513366-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:14513366-Cyclins,
pubmed-meshheading:14513366-Dose-Response Relationship, Drug,
pubmed-meshheading:14513366-Drug Resistance, Neoplasm,
pubmed-meshheading:14513366-Enzyme Inhibitors,
pubmed-meshheading:14513366-Female,
pubmed-meshheading:14513366-Humans,
pubmed-meshheading:14513366-Nuclear Proteins,
pubmed-meshheading:14513366-Organoplatinum Compounds,
pubmed-meshheading:14513366-Ovarian Neoplasms,
pubmed-meshheading:14513366-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:14513366-Phosphorylation,
pubmed-meshheading:14513366-Proto-Oncogene Proteins,
pubmed-meshheading:14513366-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:14513366-Tumor Suppressor Protein p53
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
|
|
pubmed:affiliation |
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Box 104, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|
